CASP9 and neoplasm: Furthermore, PYCARD silencing and methylation status has been reported in several other neoplastic diseases such as colorectal, lung and ovarian cancer, melanoma, neuroblastoma, and glioblastoma [104–109], and has typically been supposed to act as a tumor suppressor implicated in caspase-mediated apoptosis (involving predominantly CASP8 and CASP9), and mitochondrial translocation of BAX coupled to activation of CASP9, CASP2, and CASP3 [110, 111].